Antibiotics Market Report 2025

The antibiotics market size has grown strongly in recent years. It will grow from $84.68 billion in 2024 to $89.31 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increased incidence of infectious diseases, growing population and urbanization, rising healthcare awareness, access to healthcare services, prevalence of antibiotic-resistant strains.

The antibiotics market size is expected to see strong growth in the next few years. It will grow to $110.65 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to global health threats, rising healthcare expenditure, government initiatives and regulations, increased international collaboration. Major trends in the forecast period include development of oral antibiotics, collaboration and partnerships for antibiotic development, regulatory incentives and pathways, antimicrobial stewardship programs in healthcare, global health initiatives for antibiotic access.

The anticipated rise in bacterial infections is poised to be a significant driver for the antibiotics market. Bacterial infections, caused by microscopic single-celled organisms, can be effectively treated and prevented using antibiotics, which impede bacterial growth. A case in point from February 2023, as reported by the World Health Organization, highlighted that 30 countries worldwide were affected by a cholera epidemic in 2022, recording the highest case fatality ratio (CFR) of 1.9% in a decade in 2021. Moreover, data from the Centers for Disease Control and Prevention in April 2023 indicated a 32% increase in syphilis cases in the United States in 2021 compared to 2020. These instances underscore the surge in bacterial infections, thereby propelling the demand for antibiotics within the market.

The escalating healthcare needs of a burgeoning population are expected to drive the growth trajectory of the antibiotics market. The burgeoning population demands increased medical resources, services, and infrastructure to address healthcare challenges effectively. Antibiotics play a pivotal role in addressing these needs by treating bacterial infections, preventing contagious diseases, and safeguarding public health. These medications aid in managing various illnesses, reducing morbidity and mortality rates, supporting medical interventions such as surgeries, chemotherapy, and immunosuppressive therapies. Adequate antibiotic usage is essential to meet the healthcare demands of a growing population and uphold global health standards. Notably, data from the U.S. Census Bureau in September 2022 indicated a 0.4% increase in the United States' resident population, reaching 333,287,557 in 2022, underscoring the imperative role of antibiotics in addressing the healthcare needs of an expanding populace, thereby driving the antibiotics market.

A prominent trend in the antibiotics market involves the rise in new product approvals, with major companies securing regulatory endorsements for their innovative antibiotic formulations. For instance, in January 2023, Alkem Laboratories Ltd., an Indian pharmaceutical firm, introduced Zidavi, a fusion of ceftazidime and avibactam. This medication is specifically designed to address complicated urinary tract infections, intra-abdominal infections, and pneumonia caused by multi-drug resistant (MDR) Gram-negative bacteria. Zidavi stands out as a pivotal advancement in combating antibiotic resistance, serving as one of the few antibiotics effective against MDR Gram-negative bacteria.

Leading companies in the antibiotics market are adopting a strategic partnership approach to improve access to novel antibacterial drugs. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve shared success and benefits. For example, in June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, announced a partnership with Cipla Limited, another India-based pharmaceutical company, to efficiently launch and distribute Cefepime-Enmetazobactam in India. This collaboration combines Orchid Pharma's expertise in innovative drug development with Cipla's vast distribution network to introduce Cefepime-Enmetazobactam, an antibiotic approved for treating complicated urinary tract infections and pneumonia. The goal is to increase access to this essential medication throughout India, while tackling the rising issue of antimicrobial resistance (AMR) and encouraging responsible antibiotic use among healthcare providers.

In July 2022, Innoviva Inc., a US-based healthcare-focused asset management company, completed the acquisition of Entasis Therapeutics Holdings Inc. for an undisclosed amount. This strategic move aims to enhance Innoviva's portfolio by introducing first-in-class antibiotics designed to address multidrug-resistant Gram-negative bacteria. The acquisition not only contributes to diversification but also facilitates the expansion of Innoviva's customer base. Entasis Therapeutics Holdings Inc., a US-based late-stage clinical biopharmaceutical company operating in the antibiotics market, is dedicated to developing, manufacturing, and marketing novel antibacterial products.

Major companies operating in the antibiotics market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb (BMS), AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Sun Pharmaceutical Industries Limited, Cipla Ltd., Ferring Pharmaceuticals, Hikma Pharmaceuticals plc, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Nabriva Therapeutics Plc.

North America was the largest region in the antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antibiotics, a class of medications, function by either eradicating bacteria or impeding their growth, aiding the body's immune system in eliminating infections. They are employed in the treatment of diverse bacterial infections.

The primary drug classes encompass penicillin, cephalosporin, aminoglycosides, tetracycline, macrolides, fluoroquinolones, sulfonamides, and others. Penicillin, derived from the fungus Penicillium, constitutes a group of antibiotics. The spectrum of activity includes broad-spectrum and narrow-spectrum antibiotics. These antibiotics can be administered through various routes, such as oral, intravenous, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They find applications in treating a range of infections, including skin infections, respiratory infections, urinary tract infections, septicemia, ear infections, gastrointestinal infections, among others.

The antibiotics market research report is one of a series of new reports that provides antibiotics market statistics, including the antibiotics industry global market size, regional shares, competitors with an antibiotics market share, detailed antibiotics market segments, market trends, and opportunities, and any further data you may need to thrive in the antibiotics industry. This antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antibiotics market consists of sales of Glycopeptides, Clindamycin, and Quinolones. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.